相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Comparison of FISH, PCR, and Immunohistochemistry in Assessing EGFR Status in Lung Adenocarcinoma and Correlation With Clinicopathologic Features
Ola A. El-Zammar et al.
DIAGNOSTIC MOLECULAR PATHOLOGY (2009)
EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer
M. Varella-Garcia et al.
JOURNAL OF CLINICAL PATHOLOGY (2009)
Oncogene Mutations, Copy Number Gains and Mutant Allele Specific Imbalance (MASI) Frequently Occur Together in Tumor Cells
Junichi Soh et al.
PLOS ONE (2009)
Epidermal Growth Factor Receptor gene amplification is acquired in association with tumor progression of EGFR-mutated lung cancer
Yasushi Yatabe et al.
CANCER RESEARCH (2008)
Biomarkers of response to epidermal growth factor receptor inhibitors in non-small-cell lung cancer working group: Standardization for use in the clinical trial setting
David A. Eberhard et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry
Ferenc Pinter et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2008)
Sequential molecular changes during multistage pathogenesis of small peripheral adenocarcinomas of the lung
Junichi Soh et al.
JOURNAL OF THORACIC ONCOLOGY (2008)
Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung
Young Tae Kim et al.
LUNG CANCER (2008)
Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer?
H. Uramoto et al.
BRITISH JOURNAL OF CANCER (2007)
Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib
F. R. Hirsch et al.
ANNALS OF ONCOLOGY (2007)
Significance of EGFR protein expression and gene amplification in non-small cell luna carcinoma
Sanja Dacic et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2006)
Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: a meta-analysis
H Nakamura et al.
THORAX (2006)
Targeted therapy for the treatment of advanced non-small cell lung cancer - A review of the epidermal growth factor receptor antagonists
GA Silvestri et al.
CHEST (2005)
Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: Molecular analysis of the IDEAL/INTACT gefitinib trials
DW Bell et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Case 1. Amplification and mutation of the epidermal growth factor receptor in metastatic lung cancer with remission from gefitinib
R Schwab et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
N Thatcher et al.
LANCET (2005)
Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer
T Takano et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Gene amplification and protein expression of EGFR and HER2 by chromogenic in situ hybridisation and immunohistochemistry in atypical adenomatous hyperplasia and adenocarcinoma of the lung
H Awaya et al.
JOURNAL OF CLINICAL PATHOLOGY (2005)
Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: A Southwest Oncology Group Study
FR Hirsch et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Erlotinib in previously treated non-small-cell lung cancer
FA Shepherd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients
H Cortes-Funes et al.
ANNALS OF ONCOLOGY (2005)
Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer
TY Chou et al.
CLINICAL CANCER RESEARCH (2005)
Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer
F Cappuzzo et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib
SW Han et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence
T Mitsudomi et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas - An immunohistomchemical and fluorescence in situ hybridization study
S Suzuki et al.
CANCER (2005)
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
H Shigematsu et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
EGFR mutations in non-small-cell lung cancer:: Analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment
A Marchetti et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib
W Pao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy
JG Paez et al.
SCIENCE (2004)
Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer
A Onn et al.
CLINICAL CANCER RESEARCH (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer - A randomized trial
MG Kris et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer
M Fukuoka et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
分享论文
